What's happening?

In light of the current situation, there is a global concern across the pharmaceutical industry around what the COVID-19 pandemic means for the global supply chain, the current pharma M&A activity taking place in the market and ultimately how CDMOs will be impacted in the long-term.

Although reports suggest that Europe may be overcoming the peak in coronavirus cases and things are starting to look up for many countries, our Recipharm teams are continuing to support their local communities in every way they can. 

Malin Källsten, Matthijs Pijnappel, Rafael Hartmann, Fredrik Lehmann, Lucia Kovac, Sara Bergström Lind, and Jonas Bergquist
Published online March 8, 2019

What is myeloma?

Gathering information and knowledge around the specific patient population and other market conditions, combined with an understanding of stability issues, will allow for a clear development strategy to be outlined and implemented.

Today, demand is for more flexible solid manufacturing capacity… The challenge lies in being able to adapt current operations to offer more flexible manufacturing operations.

We are delighted to have been awarded with Life Science Leader's CMO Leadership Award once again.

Recipharm’s reputation is built on using our expertise and capabilities to support pharmaceutical companies in taking their products from early development through to commercial manufacturing. Of course, it is our desire to bring life-saving medicines to patients that ultimately drives us.

At Recipharm, we are dedicated to supporting our customers when they need it most, particularly in these testing times since the outbreak of COVID-19. We are aware that our customers need to work quickly and efficiently, and the current travel restrictions that are in place create many challenges.

Unmet patient needs and ongoing advances in science and technology are the growth engines behind inhalation therapy.